Ascendis Pharma Announces 2-Year Results From A Post-hoc Analysis Of Their Phase 3 Pathway Trial Demonstrating Sustained Improvements In Renal Function In Adults With Chronic Hypoparathyroidism Treated With TransCon PTH
Ascendis Pharma Announces 2-Year Results From A Post-hoc Analysis Of Their Phase 3 Pathway Trial Demonstrating Sustained Improvements In Renal Function In Adults With Chronic Hypoparathyroidism Treated With TransCon PTH
Ascendis Pharma A/S (NASDAQ:ASND) today announced 2-year results from a post-hoc analysis of the Company's Phase 3 PaTHway Trial demonstrating significant and sustained improvements in renal function in adults with chronic hypoparathyroidism treated with TransCon PTH (palopegteriparatide). The data were shared in an oral presentation on May 12 by Peter Schwarz, M.D., Professor of Clinical Medicine at the University of Copenhagen, during the European Congress of Endocrinology 2024 (ECE 2024), the annual meeting of the European Society of Endocrinology.
Ascendis Pharma A/S（納斯達克股票代碼：ASND）今天公佈了對該公司3期Pathway試驗的事後分析的2年業績，該結果表明，接受TransCon PTH（palopegteriparatide）治療的慢性甲狀旁腺功能減退的成年人的腎功能明顯持續改善。哥本哈根大學臨床醫學教授彼得·施瓦茲醫學博士在歐洲內分泌學會年會2024年歐洲內分泌學大會（ECE 2024）期間於5月12日的口頭陳述中分享了這些數據。